Wecome to WEED inc.
previous arrow
next arrow

WEED, Inc. (BUDZ) is a publicly listed, publicly traded, fully reporting, PCAOB audited, Sarbanes-Oxley compliant corporation.

WEED, Inc. is a multi-national, multi-faceted, vertically integrated world-class cannabis organization focused on the development and application of strain and disease specific cannabis and hemp-derived compounds for the treatment of humans and animals. WEED, Inc.’s strategy is to develop, acquire and control the intellectual properties of patents, trademarks, copyrights, licenses, and cannabis-based products and create recognized brand names in the cannabis and hemp sectors with national and international distribution channels.

WEED, Inc. is structured as a holding company doing business through its divisions, wholly owned subsidiaries, and strategically placed collaborative partners to achieve and promote the WEED, Inc. brand.

WEED, Inc. is fully dedicated to its global goal of producing, marketing and distributing treatments, medical therapies and products utilizing the full spectrum of the Cannabaceae plant family.

Sangre BioSciences

Sangre BioSciences is focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases.


WEED Australia Ltd.

WEED Australia Ltd.’s corporate strategy is to use its proprietary research, medical patents and clinical trials to create unique medical products and services for the treatment of human and animal diseases.


WEED Israel Cannabis Ltd.

WEED Israel Cannabis Ltd. was established to build and expand WEED, Inc.’s global presence.


Big Biz Show WEED inc.

TUCSON, AZ / February 7, 2019
In this segment from the Big Biz Show WEED inc. Chairman, President, and CEO Glenn Martin talks about the history and the future of WEED inc and its subsidiaries.


WEED, Inc. Signs First-of-its-Kind Agreement on Key Cannabis-Related Intellectual Property in Israel

TUCSON, AZ / ACCESSWIRE / March 7, 2019
WEED, Inc. and Yissum (of the Hebrew University of Jerusalem) sign first-of-its-kind deal for exclusive license, assignment and transfer to WEED Inc. of groundbreaking intellectual property for novel technologies and formulations of cannabis-related and cannabinoid-based products


WEED Inc. Completes Proprietary Cannabis Genomics Pilot Study

TUCSON, AZ / ACCESSWIRE / December 11, 2018 /
WEED, Inc. (BUDZ) (the ''Company'') or (''WEED'') announced that its first of many cultivar DNA sequencing tests have been perfected and finalized...


WEED, Inc. Acquires WEED(R) Trademarks

TUCSON, AZ / ACCESSWIRE / October 18, 2018
WEED, Inc. (BUDZ), a global Cannabis holding company focused on the development and application of cannabis–derived compounds for the treatment of human diseases, announced today that it has acquired the rights to two trademark registrations...


WEED Inc. Expands Global Footprint By Entering Israel & Australia

TUCSON, AZ / ACCESSWIRE / September 10, 2018
WEED, Inc. (OTC PINK: BUDZ) (the "Company" or "WEED"), has established WEED Israel (Cannabis) Ltd. as a wholly owned subsidiary of WEED Inc (USA). WEED Israel (Cannabis) Ltd. is currently in negotiations with major universities, hospitals, charitable organizations, Kibbutz, and private & public entities to create a true "SEED-TO-SALE" company from this Holy Land...


WEED, Inc. S-1 Registration Statement Declared Effective by Securities and Exchange Commission

TUCSON, AZ / ACCESSWIRE / August 13, 2018
WEED, Inc. (OTC PINK: BUDZ) (the "Company" or "WEED"), a current alternative reporting public company focused on the development and application of cannabis-derived compounds for the treatment of human disease, announced that its Form S-1 resale registration statement relating to the resale of up to 8,982,015 shares of its common stock by certain selling shareholders (the "S-1") was declared effective by the Securities and Exchange Commission on August 8, 2018 at 4pm Eastern Time.